logo
Plus   Neg
Share
Email

Brookfield Asset Management Q4 FFO Down

Brookfield Asset Management Inc. (BAM, BAM_A.TO) reported that its funds from operations for the fourth-quarter declined to $826 million or $0.80 per share from $1.085 billion or $1.07 per share in the prior year.

Net income for the quarter grew to $1.756 billion or $0.91 per share from $941 million or $0.11 per share in the prior year.

The Board declared a quarterly dividend of US$0.16 per share (representing US$0.64 per annum), payable on December 31, 2019 to shareholders of record as at the close of business on November 29, 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
RELATED NEWS
Follow RTT